Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Sarcoma 1

Conditions

Sarcoma 4Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Fallopian Tube Neoplasms 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma, Ovarian 1Teratoma 1Stomach Neoplasms 1Stage IA Uterine Sarcoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Recurrence 1Platinum-Refractory Fallopian Tube Carcinoma 1Oropharyngeal Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Nivolumab 1Laparoscopy 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Taxes × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡